Literature DB >> 21558437

Anxiolytic-like activity of pregabalin in the Vogel conflict test in α2δ-1 (R217A) and α2δ-2 (R279A) mouse mutants.

Susan M Lotarski1, Sean Donevan, Ayman El-Kattan, Sarah Osgood, Julie Poe, Charles P Taylor, James Offord.   

Abstract

The α(2)δ auxiliary subunits (α(2)δ-1 and α(2)δ-2) of voltage-sensitive calcium channels are thought to be the site of action of pregabalin (Lyrica), a drug that has been shown to be anxiolytic in clinical trials for generalized anxiety disorder. Pregabalin and the chemically related drug gabapentin have similar binding and pharmacology profiles, demonstrating high-affinity, in vitro binding to both α(2)δ-1 and α(2)δ-2 subunits. Two independent point mutant mouse strains were generated in which either the α(2)δ-1 subunit (arginine-to-alanine mutation at amino acid 217; R217A) or the α(2)δ-2 subunit (arginine-to-alanine mutation at amino acid 279; R279A) were rendered insensitive to gabapentin or pregabalin binding. These strains were used to characterize the activity of pregabalin in the Vogel conflict test, a measure of anxiolytic-like activity. Pregabalin showed robust anticonflict activity in wild-type littermates from each strain at a dose of 10 mg/kg but was inactive in the α(2)δ-1 (R217A) mutants up to a dose of 320 mg/kg. In contrast, pregabalin was active in the α(2)δ-2 (R279A) point mutants at 10 and 32 mg/kg. The positive control phenobarbital was active in mice carrying either mutation. These data suggest that the anxiolytic-like effects of pregabalin are mediated by binding of the drug to the α(2)δ-1 subunit.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21558437     DOI: 10.1124/jpet.111.180976

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

Review 1.  Pregabalin: a review of its use in adults with generalized anxiety disorder.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2014-09       Impact factor: 5.749

2.  Systemic pregabalin attenuates sensorimotor responses and medullary glutamate release in inflammatory tooth pain model.

Authors:  N Narita; N Kumar; P S Cherkas; C Y Chiang; J O Dostrovsky; T J Coderre; B J Sessle
Journal:  Neuroscience       Date:  2012-05-17       Impact factor: 3.590

3.  Anxiolytic effects of the novel α2δ ligand mirogabalin in a rat model of chronic constriction injury, an experimental model of neuropathic pain.

Authors:  Hiroyasu Murasawa; Hiroyuki Kobayashi; Kensuke Saeki; Yutaka Kitano
Journal:  Psychopharmacology (Berl)       Date:  2019-09-12       Impact factor: 4.530

Review 4.  Injury-induced maladaptation and dysregulation of calcium channel α2 δ subunit proteins and its contribution to neuropathic pain development.

Authors:  Nian Gong; John Park; Z David Luo
Journal:  Br J Pharmacol       Date:  2017-08-01       Impact factor: 8.739

Review 5.  Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet.

Authors:  Michael A Rogawski; Wolfgang Löscher; Jong M Rho
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

6.  Cystathionine γ-lyase deficiency protects mice from galactosamine/lipopolysaccharide-induced acute liver failure.

Authors:  Kazuhiro Shirozu; Kentaro Tokuda; Eizo Marutani; David Lefer; Rui Wang; Fumito Ichinose
Journal:  Antioxid Redox Signal       Date:  2013-08-22       Impact factor: 8.401

7.  The effect of pregabalin on sensorimotor gating in 'low' gating humans and mice.

Authors:  Dean T Acheson; Murray B Stein; Martin P Paulus; Mark A Geyer; Victoria B Risbrough
Journal:  Neuropharmacology       Date:  2012-05-02       Impact factor: 5.250

8.  Pregabalin for the treatment of generalized anxiety disorder: an update.

Authors:  David S Baldwin; Khalil Ajel; Vasilios G Masdrakis; Magda Nowak; Rizwan Rafiq
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-24       Impact factor: 2.570

Review 9.  Elucidating the mechanism of action of pregabalin: α(2)δ as a therapeutic target in anxiety.

Authors:  Juan-Antonio Micó; Rita Prieto
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 6.497

Review 10.  The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential.

Authors:  Gerald W Zamponi; Joerg Striessnig; Alexandra Koschak; Annette C Dolphin
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.